Canaccord analyst Kyle Mikson raised the firm’s price target on 10x Genomics (TXG) to $22 from $20 and keeps a Buy rating on the shares. The firm said they continue to favor TXG in tools and believe the company is positioned to achieve a near-term growth reacceleration following several quarters of sequential improvement. The price target raise is primarily driven by increased revenue assumptions in the out years of their 10-year DCF model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- Maintaining a Neutral Hold: Solid Q4 Beat but Limited 2026 Growth Visibility and Valuation Upside
- 10x Genomics reports Q4 EPS (13c), consensus (4c)
- 10x Genomics sees 2026 revenue $600M-$625M, consensus $611.77M
- Cathie Wood Sells Biotech Stocks, Bets Big on Tempus AI and WeRide
- Cathie Wood Loads Up on Broadcom and Crypto Stocks, Trims Meta by $8M Ahead of Q4. Here’s Why